Tufts CSDD Study -'Assessing the Financial Impact of Translational Pharmaceutics - A Platform for Accelerating Drug Development'

Learn how results from a recent Tufts CSDD study indicate that Translational Pharmaceutics® reduces development times by >12 months and lower R&D costs by >$100 million per approved new drug.

Like Comment
Go to the profile of Quotient Sciences

Quotient Sciences

Quotient Sciences is dedicated to accelerating the development of new drugs for patients around the world. We provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
5 Contributions
3 Followers
2 Following

No comments yet.